This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...
Cumulative net returns improved 20% for 4Q24 and were 39% for full year. Since inception through 2024-end, LCA returned a cumulative 270% net of fees, or 15% CAGR. Read more here.